Wetenschappelijke publicaties van Bordet

Wetenschappelijke publicaties van Bordet

Corrigendum to \"Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial\" [The Breast 83 (2025) 104547].

Demeestere I, Niman SM, Partridge AH, Diego DS, Kammler R, Ruggeri M, Colleoni M, Shimizu C, Saura C, Gelmon KA, Saetersdal AB, Kroep JR, Mailliez A, Amant F, Ruız-Borrego M, Lee JE, Kataoka A, Walshe JM, Takei J, Borstnar S, Borges VF, Saunders C, Susnjar S, Bjelic-Radisic V, Cardoso F, Meisel JL, Kawwass JF, Spanic T, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Azim HA, Peccatori FA

Corrigendum to \"Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial\" [The Breast 83 (2025) 104547].

Assessing the oncologic risk when systematic and multiparametric magnetic resonance imaging-targeted prostate biopsy grade groups are discordant.

Scuderi S, Tin AL, Marra G, Bianchi L, Kesch C, Soeterik TFW, Ploussard G, Zattoni F, Ettala O, Røder A, Poyet C, Stroomberg HV, Cimmino U, Fiard G, Nordström T, Patel HD, Gupta GN, Yonover PM, Guillaume B, Gaffney C, Zhuang J, Wang Y, Sarkis J, Jabbour T, Diamand R, Windisch O, Olivier J, Abbadi A, Kim EH, Wang JC, Hu J, Zhu A, Stabile A, Eastham JA, Montorsi F, Briganti A, Gandaglia G, Vickers AJ

Assessing the oncologic risk when systematic and multiparametric magnetic resonance imaging-targeted prostate biopsy grade groups are discordant.

Complete remission with olaparib in BRIP1-mutated metastatic high-grade pleomorphic sarcoma: case study and literature review - an example of a genomic profiling-based tumor treatment, in a cancer type with high unmet clinical need.

Thooft ADJ, Joris S, Jacobs C, Creytens D, Rottey S, Maes B, Aftimos P, Lapeire L

Complete remission with olaparib in BRIP1-mutated metastatic high-grade pleomorphic sarcoma: case study and literature review - an example of a genomic profiling-based tumor treatment, in a cancer type with high unmet clinical need.

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

Modi S, Jacot W, Iwata H, Park YH, Vidal Losada M, Li W, Tsurutani J, Ueno NT, Zaman K, Prat A, Papazisis K, Rugo HS, Yamashita T, Harbeck N, Im SA, De Laurentiis M, Pierga JY, Wang X, Gombos A, Tokunaga E, Orbegoso Aguilar C, Yung L, Xiao F, Cheng Y, Cameron D

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer.

Jacobs F, D'Amico S, Ferraro E, Agostinetto E, Tondini C, Gaudio M, Benvenuti C, Gerosa R, Saltalamacchia G, Zazzetti E, Di Rienzo R, Buonaiuto R, Martorana F, Chirco A, De Sanctis R, Della Porta MG, Santoro A, Vigneri P, Arpino MG, Giuliano M, Fornier M, de Azambuja E, Zambelli A

RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer.
Erasme hospital

Erasmusziekenhuis

Bekijk alle wetenschappelijke publicaties van Erasmus

Wetenschappelijke publicaties van Erasmus
Huderf hospital

Queen Fabiola Kinderziekenhuis

Bekijk alle wetenschappelijke publicaties van het Koningin Fabiola Kinderziekenhuis

Wetenschappelijke publicaties van het Koningin Fabiola-Kinderziekenhuis
Bordet hospital

Jules Bordet-instituut

Bekijk alle wetenschappelijke publicaties van Jules Bordet

Wetenschappelijke publicaties van Jules Bordet